Cardiac Progenitor Cell Isolation via Enzymatic Digestion and Magnetic Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for isolating cardiac progenitor cells from heart tissue samples are inefficient in obtaining clinically significant numbers and high purity, particularly in GMP-grade conditions, limiting their application in clinical trials and therapies.
Innovation Solution
A method involving progressive enzymatic digestion, filtration, and secondary expansion of cardiac cells using specific culture media and monoclonal antibodies for immunomagnetic selection, allowing for the isolation of subpopulations from small tissue samples with maintained phenotypic characteristics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If magnetic selection system is used to isolate cardiac progenitor cells, then cell purity is improved, but the starting cell number requirement increases to 1×10^9 cells
Solution Approach 1:
The patent applies preliminary expansion of cardiac progenitor cells in culture before magnetic selection. The cells are first expanded in vitro to increase their number, then subjected to magnetic selection using CD117 antibodies. This preliminary expansion action allows the magnetic selection system to work effectively with smaller original tissue samples, resolving the contradiction between maintaining high purity and reducing starting cell requirements.
2Quantity of substance
If extensive expansion of starting population is performed, then selectable cell number is improved, but culture time and process duration increase
Solution Approach 1:
The patent optimizes culture parameters including using specific growth media formulations, controlling cell density, and adjusting incubation conditions to accelerate the expansion phase. By changing these cultural parameters, the expansion process is made more efficient, producing sufficient cell numbers in reduced timeframes, thus resolving the contradiction between cell quantity and time investment.
3Reliability
If GMP-grade selection system is used, then production quality is improved, but adaptability to small tissue samples is worsened
Solution Approach 1:
The patent performs preliminary expansion of cells from small tissue samples in GMP-compliant conditions before applying the magnetic selection system. This preliminary action in controlled culture allows the system to adapt to small sample inputs while maintaining GMP-grade quality standards throughout the process, resolving the contradiction between production quality and sample size adaptability.
4Reliability
If cardiac progenitor cells are isolated for clinical trials, then therapeutic potential is improved, but regulatory compliance requirements increase
Solution Approach 1:
The patent develops a universal isolation protocol that integrates both research flexibility and GMP compliance requirements into a single standardized process. The method uses standardized reagents, controlled procedures, and documented protocols that satisfy regulatory requirements while maintaining the therapeutic potential of the isolated cells, thus resolving the contradiction between therapeutic benefits and regulatory complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables the efficient expansion and isolation of cardiac progenitor cells in a controlled manner, achieving clinically significant numbers with high purity and versatility, suitable for GMP-grade conditions, and applicable in various heart diseases and therapies.
Implementation Method 1
isolating one or more subpopulations of cardiac cells by positive and/or negative selection by the use of monoclonal antibodies directed against one or more surface antigens expressed in the starting population of cardiac progenitor cells
Implementation Method 2
progressive digestion of the cardiac tissue with an enzymatic mixture until a cell suspension is achieved
Data Source
AI summary
The present invention relates to a method for the isolation of subpopulations of cardiac progenitor cells from a heart tissue sample, the population thus obtained and the related uses in the medical field for the cell therapy or cardiac cell and/or tissue transplantation field.